ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO140

Incidence of Cardiovascular Diseases in Pediatric Solid Organ Transplant Recipients

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical


  • Brar, Sandeep, University of Toronto, Toronto, Ontario, Canada
  • Dixon, Stephanie, Institute for Clinical Evaluative Sciences, London, Ontario, Canada
  • Paterson, John Michael, Institute for Clinical Evaluative Sciences, London, Ontario, Canada
  • Kim, Joseph, University of Toronto, Toronto, Ontario, Canada
  • Hebert, Diane, University of Toronto, Toronto, Ontario, Canada
  • Dirk, Jade S., Institute for Clinical Evaluative Sciences, London, Ontario, Canada
  • Hahn, Emma J., Institute of Clinical Evaluative Sciences, London, Ontario, Canada
  • Parekh, Rulan S., The Hospital For Sick Children, Toronto, Ontario, Canada
  • Chanchlani, Rahul, McMaster Children’s Hospital, Hamilton, Ontario, Canada

Cardiovascular disease (CVD) is a long-term complication in pediatric solid organ transplant (SOT) recipients; however, the incidence is not well described.


We conducted a cohort study comparing CVD rates in children with SOT (heart, liver, lung, kidney, small bowel) at the Hospital for Sick Children in Toronto, Canada (n = 979) with a random sample of healthy, non-transplanted children in Ontario (n = 1,000,000) between 1993 and 2014 using provincial health administrative data. Outcomes included non-fatal CVD events, CVD-specific death, and a composite of non-fatal and fatal CVD events. Non-fatal CVD events were defined as atherosclerotic (acute myocardial infarction, stroke, peripheral vascular disease, carotid endarterectomy, percutaneous coronary intervention, coronary artery bypass grafting) and non-atherosclerotic (congestive heart failure, arrhythmia, cardiac defibrillation, insertion of pacemaker, out of hospital cardiac arrest).


Among SOT recipients, 41% had a kidney transplant, 32% had a liver transplant and 22% had a cardiac transplant. The remaining 5% had lung, small bowel or multi-organ transplants. Mean age at index was 7.7 and 8.1 years in the transplant and non-transplant group, respectively. During an overall median follow-up time of 11.0 years (interquartile range: 5.7-17.5 years), CVD events were at least 50 times more likely to occur in SOT recipients versus healthy, non-transplanted children (table).


The increased incidence of CVD in children post transplantation highlights the need for surveillance and prevention during transition into early adulthood.

Events and incidence rate ratios for cardiovascular outcomes in pediatric solid organ transplant recipients
OutcomeNumber of eventsEvent rate per 1000 person-yearsIncidence rate ratio (per 1000 person-years) (95% CI)
Non-fatal composite
Transplant26032.568.2 (60.2, 77.2)
Non-fatal, atherosclerotic CVD
Transplant16719.575.7 (64.8, 88.4)
Non-fatal, non-atherosclerotic CVD
Transplant16719.552.9 (45.5, 61.5)
CVD-specific death
Transplant769.5180.3 (142.1, 228.7)
Non-fatal and fatal composite
Transplant27834.768.8 (61.0, 77.5)